Piper Sandler on Axsome Therapeutics (AXSM): 'A High-Risk, High-Reward Opportunity'

April 2, 2026 8:28 AM

Piper Sandler analyst David Amsellem reiterated an Overweight rating and $223.00 price target on Axsome Therapeutics (NASDAQ: AXSM).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found